CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.25, moving +1.38% from the previous trading session.

Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Detailed price information for Meta Platforms Inc (META-Q) from The Globe and Mail including charting and trades.

Cathie Wood’s ARK ETFs have made significant moves in the stock market on Wednesday, April 30th, 2025, with Advanced Micro ...

CRISPR Therapeutics' revenue streams currently rely heavily on grants and collaboration revenues from its partnership with Vertex Pharmaceuticals (VRTX). The collaboration has yielded Casgevy, a ...

Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) are two incredibly innovative biotechs, but ...

Another notable trade was the sale of 67,053 shares of Schrödinger Inc (NASDAQ: SDGR) by the ARKG ETF, valued at $1,726,614.

Cathie Wood's ARK Invest has increased its stake in a Chinese technology giant an equity favored by Michael Burry.

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CRSP has been the subject of a number of other reports. Bank of America decreased their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...